Literature DB >> 19333543

Interstitial cells of Cajal do not harbor c-kit or PDGFRA gene mutations in patients with sporadic gastrointestinal stromal tumors.

Takahiko Nakajima1, Shigeharu Miwa, Takayuki Ando, Haruka Fujinami, Shinya Kajiura, Ayumu Hosokawa, Yasuo Takano, Toshiro Sugiyama.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are believed to originate from the interstitial cells of Cajal (ICCs) or from the precursors of ICCs. Most GISTs show an activating mutation in either the c-kit or platelet-derived growth factor receptor alpha (PDGFRA) gene that results in a constitutive, ligand-independent activation of receptor tyrosine kinases. These gene mutations may play an important role in transforming a GIST progenitor cell into a tumor cell during the early phase of GIST tumorigenesis. However, the precise mechanism of the tumorigenesis is not known.
METHODS: We examined ten patients with sporadic GIST for mutations in the tumor and its adjacent ICC cells, and compared the mutational status of ICC cells with that of the GIST cells in each patient. All cases were screened for mutations in the c-kit gene (exons 9, 11, 13, and 17) and in the PDGFRA gene (exons 12 and 18). Samples were limited to GIST cases from the small intestine, where ICCs were present in bundles and were considered suitable for isolation by laser capture microdissection.
RESULTS: Of the ten tumors screened, eight had mutations in the c-kit gene (all in exon 11) and two were wild-type, whereas none of the ICCs exhibited mutations in these genes.
CONCLUSIONS: Our results suggest that ICCs adjacent to overt GISTs did not have mutations in the c-kit or PDGFRA genes, and overt GISTs may develop after the local and sporadic acquisition of these gene mutations, together with additional events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19333543     DOI: 10.1007/s00535-009-0032-z

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  23 in total

1.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authors:  H Joensuu; P J Roberts; M Sarlomo-Rikala; L C Andersson; P Tervahartiala; D Tuveson; S Silberman; R Capdeville; S Dimitrijevic; B Druker; G D Demetri
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital.

Authors:  Tokimasa Kumada; Koichi Tsuneyama; Hideki Hatta; Shin Ishizawa; Yasuo Takano
Journal:  Mod Pathol       Date:  2004-09       Impact factor: 7.842

3.  c-Kit immunoreactive interstitial cells in the human gastrointestinal tract.

Authors:  S Torihashi; M Horisawa; Y Watanabe
Journal:  J Auton Nerv Syst       Date:  1999-01-15

4.  Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.

Authors:  Karin Hartmann; Eva Wardelmann; Yongsheng Ma; Sabine Merkelbach-Bruse; Liane M Preussner; Carla Woolery; Stephan E Baldus; Thomas Heinicke; Juergen Thiele; Reinhard Buettner; B Jack Longley
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

5.  High incidence of microscopic gastrointestinal stromal tumors in the stomach.

Authors:  Kaori Kawanowa; Yuji Sakuma; Shinji Sakurai; Tsunekazu Hishima; Yoshiaki Iwasaki; Kana Saito; Yoshinori Hosoya; Takashi Nakajima; Nobuaki Funata
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

6.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

Authors:  D A Tuveson; N A Willis; T Jacks; J D Griffin; S Singer; C D Fletcher; J A Fletcher; G D Demetri
Journal:  Oncogene       Date:  2001-08-16       Impact factor: 9.867

7.  Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours.

Authors:  H Chen; S Hirota; K Isozaki; H Sun; A Ohashi; K Kinoshita; P O'Brien; L Kapusta; I Dardick; T Obayashi; T Okazaki; Y Shinomura; Y Matsuzawa; Y Kitamura
Journal:  Gut       Date:  2002-12       Impact factor: 23.059

8.  A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors.

Authors:  Inigo Espinosa; Cheng-Han Lee; Mi Kyung Kim; Bich-Tien Rouse; Subbaya Subramanian; Kelli Montgomery; Sushama Varma; Christopher L Corless; Michael C Heinrich; Kevin S Smith; Zhong Wang; Brian Rubin; Torsten O Nielsen; Robert S Seitz; Douglas T Ross; Robert B West; Michael L Cleary; Matt van de Rijn
Journal:  Am J Surg Pathol       Date:  2008-02       Impact factor: 6.394

9.  Gastrointestinal stromal tumors--value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas.

Authors:  M Miettinen; M Virolainen
Journal:  Am J Surg Pathol       Date:  1995-02       Impact factor: 6.394

10.  PDGFRA activating mutations in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Anette Duensing; Laura McGreevey; Chang-Jie Chen; Nora Joseph; Samuel Singer; Diana J Griffith; Andrea Haley; Ajia Town; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

View more
  1 in total

1.  Multiple Synchronous Sporadic Gastrointestinal Stromal Tumors in the Stomach and Jejunum.

Authors:  Mami Tokunaga; Sohachi Nanjo; Hiroki Yoshita; Haruka Fujinami; Tohru Watanabe; Yoko Ishii; Saito Kobayashi; Momoko Akashi; Hiroaki Takagi; Hiroshi Mihara; Shinya Kajiura; Takayuki Ando; Isaya Hashimoto; Shozo Hojo; Tomoyuki Okumura; Toshiro Sugiyama
Journal:  Intern Med       Date:  2018-02-09       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.